HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Interstitial lung disease during chemotherapy combined with oxaliplatin and/or bevacizumab in advanced colorectal cancer patients.

AbstractOBJECTIVE:
Interstitial lung disease in patients with colorectal cancer during chemotherapy combined with bevacizumab is rare.
METHODS:
We reviewed 104 colorectal cancer patients treated with standard chemotherapy with bevacizumab and examined the incidence of interstitial lung disease and its clinical features.
RESULTS:
We identified interstitial lung disease in four patients (3.85%). All patients were male. The median age was 64.5 years. Three of four patients had a history of smoking; median smoking index was 40 pack-years. Except one patient who had asymptomatic pulmonary fibrosis, chest computed tomography before chemotherapy showed no fibrotic changes. Pulmonary function test before chemotherapy showed normal values. All patients had received median 10 cycles (range 10-15 cycles) of FOLFOX before the onset of interstitial lung disease. Interstitial lung disease developed during FOLFOX + bevacizumab in two patients and during FOLFIRI + bevacizumab in two patients. The initial symptom of interstitial lung disease was fever in all patients. The median duration from the last chemotherapy to the onset of interstitial lung disease was 3.5 days (range 2-8 days). Three of four patients showed Grade 3 or more severity of interstitial lung disease according to Common Terminology Criteria for Adverse Events v3.0. High-dose steroid therapy was effective in all patients.
CONCLUSIONS:
Interstitial lung disease induced by standard chemotherapy with bevacizumab is rare, but rapidly progressed and were severe in our experience.
AuthorsKazuhiro Usui, Yuu Katou, Kaoru Furushima, Yoshiaki Tanaka, Chiharu Tanai, Teruo Ishihara
JournalJapanese journal of clinical oncology (Jpn J Clin Oncol) Vol. 41 Issue 4 Pg. 498-502 (Apr 2011) ISSN: 1465-3621 [Electronic] England
PMID21303791 (Publication Type: Journal Article)
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Organoplatinum Compounds
  • Oxaloacetates
  • Oxaliplatin
  • Deoxycytidine
  • Bevacizumab
  • Capecitabine
  • Leucovorin
  • Fluorouracil
  • Camptothecin
Topics
  • Acute Disease
  • Adult
  • Aged
  • Aged, 80 and over
  • Alveolitis, Extrinsic Allergic (chemically induced, diagnostic imaging, etiology)
  • Antibodies, Monoclonal (administration & dosage, adverse effects)
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols (administration & dosage, adverse effects, therapeutic use)
  • Bevacizumab
  • Camptothecin (administration & dosage, adverse effects, analogs & derivatives)
  • Capecitabine
  • Colorectal Neoplasms (drug therapy, pathology)
  • Deoxycytidine (administration & dosage, adverse effects, analogs & derivatives)
  • Disease-Free Survival
  • Fluorouracil (administration & dosage, adverse effects, analogs & derivatives)
  • Humans
  • Japan
  • Leucovorin (administration & dosage, adverse effects)
  • Lung Diseases, Interstitial (chemically induced)
  • Male
  • Medical Records Systems, Computerized
  • Middle Aged
  • Organoplatinum Compounds (administration & dosage, adverse effects)
  • Oxaliplatin
  • Oxaloacetates
  • Pulmonary Fibrosis (chemically induced, diagnostic imaging, etiology)
  • Retrospective Studies
  • Severity of Illness Index
  • Smoking (adverse effects)
  • Tomography, X-Ray Computed

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: